MedTrace Logo

Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab

NCT01328366 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 153

Last updated 2015-07-09

Study results available
· View outcomes & findings →

Summary

The impact of psoriasis on an individual's emotional and social well-being goes beyond skin symptoms of the disease. Data suggests patients with severe psoriasis experience a greater prevalence of depressive symptoms, mood disturbances, anxiety and even suicidal ideation. Given the nature of the disease and the treatment failures which are required before a patient commences a biologic therapy such as adalimumab, the patient's mental health at initiation of biologics is an important consideration for clinicians. This study seeks to explore if adalimumab treatment of psoriasis leads to a positive impact on psychosocial factors and disease-related quality of life.

Conditions

Sponsors & Collaborators

  • pH Associates

    collaborator UNKNOWN

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Neil Pumford, MD · AbbVie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2014-05-31
Completion
2014-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01328366 on ClinicalTrials.gov